Norfolk and Norwich University Hospitals (NNUH) NHS Foundation Trust
The Metabolic Bone Disease Unit that was previously located the Royal Liverpool University Hospital site for over 30 years moved to Norfolk and Norwich University Hospital in 2011. Both clinical and academic aspects of the management and investigation of bone metabolism were developed under the direction of Professor Bill Fraser. An international reputation has been established in the development, evaluation and application of assays for calcitropic hormones (PTH, PTHrP, vitamin D metabolites (25-OHD, 1,25 (OH)2 D, 24,25 (OH)2 D), bone/collagen metabolism (pyridinoline cross-links (PYD,DPD) telopeptides (CTX,NTX), pro-collagen molecules (P1NP, PIIINP), osteocalcin, TRAP5b and bone specific alkaline phosphatase) and intact and C-terminal fibroblast growth factor 23 (FGF23). The majority of these assays are available with 2-3 week turnaround and a national/international service is provided for PTHrP. Other assays are available in a research capacity e.g. vitamin D binding protein, sclerostin, RANKL, osteoprotegrin and alpha klotho, for example. Investigation protocols, consultation and advice are available for all aspects of bone and calcium metabolism as part of the SAS.
Director: Professor Bill Fraser
Deputy Director: Dr Allison Chipchase
Tel: +44 (0)1603 287945
Norfolk and Norwich University Hospitals NHS Foundation Trust
Metabolic Bone Marker Laboratory
Level 1 East Block
UPDATE: Please be aware, our PTHrP service is currently suspended following the change by our assay manufacturer of their capture antibody. We are currently developing a LC-MS assay for PTHrP and will update these pages when the new assay is available clinically.